Literature DB >> 23425945

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.

M Dreyling1, C Thieblemont, A Gallamini, L Arcaini, E Campo, O Hermine, J C Kluin-Nelemans, M Ladetto, S Le Gouill, E Iannitto, S Pileri, J Rodriguez, N Schmitz, A Wotherspoon, P Zinzani, E Zucca.   

Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organizes consensus conferences to focus on specific issues in each type of tumour. In this setting, a consensus conference on the management of lymphoma was held on 18 June 2011 in Lugano, next to the 11th International Conference on Malignant Lymphoma. The conference convened ∼30 experts from all around Europe, and selected six lymphoma entities to be addressed; for each of them, three to five open questions were to be addressed by the experts. For each question, a recommendation should be given by the panel, referring to the strength of the recommendation based on the level of evidence. This consensus report focuses on the three less common lymphoproliferative malignancies: marginal zone lymphoma, mantle cell lymphoma, and peripheral T-cell lymphomas. A first report had focused on diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukaemia.

Entities:  

Mesh:

Year:  2013        PMID: 23425945     DOI: 10.1093/annonc/mds643

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  70 in total

1.  Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials.

Authors:  E Hoster; C H Geisler; J Doorduijn; B van der Holt; J Walewski; J Bloehdorn; V Ribrag; G Salles; M Hallek; C Pott; M Szymczyk; A Kolstad; A Laurell; R Räty; M Jerkeman; M Van't Veer; J C Kluin-Nelemans; W Klapper; M Unterhalt; M Dreyling; O Hermine
Journal:  Leukemia       Date:  2015-11-24       Impact factor: 11.528

2.  Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma.

Authors:  S Dietrich; J Weidle; M Rieger; J Meissner; A Radujkovic; A D Ho; P Dreger; M Witzens-Harig
Journal:  Leukemia       Date:  2013-11-12       Impact factor: 11.528

3.  How to manage mantle cell lymphoma.

Authors:  M Dreyling; S Ferrero; O Hermine
Journal:  Leukemia       Date:  2014-05-23       Impact factor: 11.528

Review 4.  Mantle cell lymphoma concurrent with T-large granular lymphocytic leukemia: report of a case and review of literature.

Authors:  Zhengrui Xiao; Ying Ni; Guangli Yin; Hanxin Wu; Jianyong Li; Kourong Miao
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

5.  Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.

Authors:  Koji Izutsu; Yosuke Minami; Noriko Fukuhara; Yasuhito Terui; Tatsuro Jo; Go Yamamoto; Takayuki Ishikawa; Tsutomu Kobayashi; Toru Kiguchi; Hirokazu Nagai; Tomoko Ohtsu; Stacey Kalambakas; Pierre Fustier; Shuichi Midorikawa; Kensei Tobinai
Journal:  Int J Hematol       Date:  2019-12-19       Impact factor: 2.490

6.  The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.

Authors:  E Sánchez-Tilló; L Fanlo; L Siles; S Montes-Moreno; A Moros; G Chiva-Blanch; R Estruch; A Martinez; D Colomer; B Győrffy; G Roué; A Postigo
Journal:  Cell Death Differ       Date:  2013-09-06       Impact factor: 15.828

7.  The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.

Authors:  S Robinson; P Dreger; D Caballero; P Corradini; C Geisler; M Ghielmini; S Le Gouill; E Kimby; S Rule; U Vitolo; M Dreyling; O Hermine
Journal:  Leukemia       Date:  2014-07-18       Impact factor: 11.528

Review 8.  Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?

Authors:  Barbara Vannata; Luca Arcaini; Emanuele Zucca
Journal:  Ther Adv Hematol       Date:  2015-12-29

9.  18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience.

Authors:  Domenico Albano; Mattia Bertoli; Paola Ferro; Federico Fallanca; Luigi Gianolli; Maria Picchio; Raffaele Giubbini; Francesco Bertagna
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-09-12       Impact factor: 9.236

Review 10.  Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas.

Authors:  Marta-Isabel Pereira; José Augusto Medeiros
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.